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Abstract
Aging and chronic disease such as type 2 diabetes (T2D) are associated with
impairments in the body’s ability to dissipate heat. To reduce the risk of heat-
related injuries in these heat vulnerable individuals, it is necessary to identify
interventions that can attenuate this impairment. We evaluated the hypothesis
that intradermal administration of ascorbate improves cutaneous vasodilation
and sweating in older adults via nitric oxide synthase (NOS)-dependent mech-
anisms during exercise in the heat and whether these improvements, if any,
are greater in individuals with T2D. Older males with (n = 12, 61  9 years)
and without (n = 12, 64  7 years) T2D performed two 30-min bouts of
cycling at a fixed rate of metabolic heat production of 500 W (~70% peak
oxygen uptake) in the heat (35°C); each followed by a 20- and 40-min recov-
ery, respectively. Cutaneous vascular conductance (CVC) and sweat rate were
measured at four intradermal microdialysis sites treated with either (1)
lactated Ringer (Control), (2) 10 mmol/L ascorbate (an antioxidant), (3) 10
mmol/L L-NAME (non-selective NOS inhibitor), or (4) a combination of
ascorbate + L-NAME. In both groups, ascorbate did not modulate CVC or
sweating during exercise relative to Control (all P > 0.05). In comparison to
Control, L-NAME alone or combined with ascorbate attenuated CVC during
exercise (all P ≤ 0.05) but had no influence on sweating (all P > 0.05). We
show that in both healthy and T2D older adults, intradermal administration
of ascorbate does not improve cutaneous vasodilation and sweating during
exercise in the heat. However, NOS plays an important role in mediating
cutaneous vasodilation.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2017 | Vol. 5 | Iss. 7 | e13238
Page 1
Physiological Reports ISSN 2051-817X
doi: 10.14814/phy2.13238
Physiol Rep, 5 (7), 2017, e13238,
doi: 10.14814/phy2.13238
Introduction
Older adults are at greater risk of heat-related injuries
(e.g., heat syncope and heat stroke), likely due to attenu-
ated cardiovascular and thermoregulatory function rela-
tive to their younger counterparts (Worfolk 2000; Kenney
et al. 2014; Kenny et al. 2016a). In parallel, although
nitric oxide (NO) synthase (NOS) is known to contribute
to the regulation of cutaneous vasodilation (Kellogg et al.
1998; Shastry et al. 2000; Welch et al. 2009; Fujii et al.
2014b; McNamara et al. 2014) and sweating (Welch
et al. 2009; Fujii et al. 2014b; Stapleton et al. 2014; Louie
et al. 2016) during heat stress in young adults, these con-
tributions are diminished in older adults (Stanhewicz
et al. 2013; Stapleton et al. 2014; Fujii et al. 2015b,
2016b). As a potential mechanism, aging is known to
increase the level of reactive oxygen species (i.e., oxidative
stress) such as superoxide (Durrant et al. 2009), which
can reduce NO bioavailability (Fujii et al. 2014a). Hence,
in older adults, the nonselective antioxidant ascorbate
may improve cutaneous vasodilation and sweating via
NOS-dependent mechanisms during heat stress, such as
that which occurs during exercise in the heat.
Individuals with type 2 diabetes mellitus are at
increased risk of heat-related injuries (Semenza et al.
1999; Kenny et al. 2016b). This is likely secondary to an
attenuation in whole-body heat dissipation (Kenny et al.
2013) associated with reductions in local cutaneous
vasodilation (Wick et al. 2006; Sokolnicki et al. 2009) and
sweating (Fealey et al. 1989; Petrofsky et al. 2005); albeit
due to regional heterogeneity, reductions in local heat loss
responses are not always observed (Kenny et al. 2013,
2016b). Individuals with type 2 diabetes have been shown
to have increased oxidative stress relative to healthy older
adults without type 2 diabetes (Folli et al. 2011; Casoinic
et al. 2016; Restaino et al. 2016), which as mentioned
above, may result in attenuations in the heat loss
responses via mechanisms related to NO. Ascorbate may
therefore augment the heat loss responses during exercise
in the heat in older adults with type 2 diabetes to a
greater extent compared to healthy older adults.
This study evaluated the effect of local ascorbate
administration on the regulation of cutaneous vasodila-
tion and sweating response during exercise in the heat in
older adults with and without type 2 diabetes. We
hypothesized that reducing oxidative stress improves the
heat loss responses of cutaneous vasodilation and sweat-
ing by increasing NOS-derived NO in both healthy older
adults and those with type 2 diabetes during exercise in
the heat, with the latter group experiencing comparatively
greater improvements.
Materials and Methods
Ethical approval
This study was approved by the University of Ottawa
Health Sciences and Science Research Ethics Board and
adhered to the guidelines set forth by the Declaration of
Helsinki. Verbal and written informed consent was
acquired from all volunteers before the initiation of any
experimental procedures.
Participants
Twelve older males diagnosed with type 2 diabetes mellitus
(T2D) for at least 5 years and twelve healthy nondiabetic
older males (Control) participated in this study. All partici-
pants were free of respiratory disease, heart disease, uncon-
trolled hypertension, and neuropathy. Participant
characteristics are described in Table 1. All participants
with T2D were taking the following medications (number
Table 1. Participant characteristics
Control group T2D group
Number of participants 12 12
Age (years) 64  7 61  9
Height (m) 1.75  0.05 1.70  0.061
Body mass (kg) 83.0  8.5 87.5  18.7
Body surface area (m2) 1.99  0.11 1.98  0.22
Body fat (%) 31  6 30  6
Peak oxygen uptake (L /min) 2.6  0.3 2.3  0.5
(mL/kg/min) 31.9  4.2 27.0  4.81
HbA1C (%) – 7.4  1.1
Duration of diabetes (years) n/a 7.5  4.4
All values are expressed as mean  standard deviation. T2D, type
2 diabetes. HbA1C, hemoglobin A1c. n/a, not applicable.
1versus Control group (P ≤ 0.05).
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of subjects are indicated in parenthesis): metformin (12),
statin (6), dipeptidyl peptidase-4 inhibitor (6), sulfonylurea
(6), angiotensin converting enzyme inhibitor (4), acetylsali-
cylic acid (4), insulin (3), angiotensin receptor blocker (3),
calcium channel blocker (2), sodium/glucose cotransporter
2 inhibitor (1), beta-blocker (1), and diuretic (1). All sub-
jects in the Control group were without prescription medi-
cations. All participants were nonsmoking for at least 5
years.
Experimental design
All participants completed one preliminary and one exper-
imental session on separate days. Participants were asked
to refrain from consuming alcohol, caffeine, and heavy
exercise at least 12 h prior to the start of the sessions. On
the day of each session, participants were allowed to have
food 2 h before the experiment. Experimental trials were
performed at different periods during the day depending
on individual schedules. During the preliminary session,
body mass, height, body surface area, body fat, and peak
oxygen uptake were determined. Body height was mea-
sured using a stadiometer (Model 2391, Detecto Scale
Company, Webb City, MO), and body mass was measured
by a digital weight scale platform (model CBU150X, Met-
tler Toledo Inc., Mississauga, ON, Canada). Body surface
area was calculated using body mass and height (DuBois
and DuBois 1916). Hydrostatic weighing was used to esti-
mate body fat percentage (Siri 1956). Peak oxygen uptake
on a semirecumbent cycle ergometer (Corival Recumbent,
Lode B.V., Groningen, Netherlands) was evaluated using
an automated indirect calorimetry system (Medgraphics
Ultima, Medical Graphics Corporation, St Paul, MN) as
previously reported (Fujii et al. 2016a).
On the day of the experimental session, body mass was
measured then participants changed into shorts and run-
ning shoes. Thereafter, participants were transferred to a
thermoneutral room (~23°C) where they were seated in a
semirecumbent position and were instrumented with four
microdialysis fibers (MD2000, Bioanalytical Systems, West
Lafayette, IN) in the dermal layer of the skin on the dor-
sal side of the left forearm. These fibers have a semiper-
meable membrane (30 kDa cutoff, 10 mm), through
which pharmacological agents can be continuously deliv-
ered into the dermis, ultimately affecting skin vessels and
sweat glands. In order to situate the fibers subcuta-
neously, a 25-gauge needle was inserted into the skin
using aseptic technique. The entry and exit points of fiber
insertion were separated by ~2.5 cm. The microdialysis
fiber was then threaded through the lumen of the needle,
after which the needle was withdrawn leaving the fiber in
place. The location of each microdialysis fiber was sepa-
rated by 2–4 cm.
Once all four fibers were placed in the skin, each
microdialysis site was perfused with lactated Ringer (Bax-
ter, Deerfield, IL) at a constant rate of 4 lL/min with a
micro-infusion pump (Model 400, CMA Microdialysis,
Solna, Sweden) for approximately 30 min. Thereafter, the
participants moved to a thermal chamber (Can-Trol Envi-
ronmental Systems Limited, Markham, ON, Canada) reg-
ulated to an ambient air temperature of 35°C and a
relative humidity of 20% where they rested on a semire-
cumbent cycle ergometer (Corival Recumbent, Lode B.V.)
and perfusion of pharmacological agents through each
microdialysis fiber began. The four sites were continuously
perfused in a counterbalanced manner with either (1) lac-
tated Ringer (Baxter, Deerfield, IL, US) (vehicle control),
(2) 10 mmol/L ascorbate, a known antioxidant (Sigma-
Aldrich, St. Louis, MO), (3) 10 mmol/L NG-nitro-L-argi-
nine methyl ester (L-NAME), a nonselective NOS inhibitor
(Sigma-Aldrich), or (4) a combination of 10 mmol/L
ascorbate and 10 mmol/L L-NAME (ascorbate +
L-NAME). These concentrations were determined based
on previous studies in which intradermal microdialysis
was employed in human skin (Holowatz and Kenney
2007; Stewart et al. 2008; Yamazaki 2010; Medow et al.
2011; Fujii et al. 2015a; Meade et al. 2015). Each infusion
was performed at a constant rate of 4.0 lL/min for at
least 60 min prior to data collection to ensure action of
each drug. Furthermore, ~90 min elapsed between fiber
insertion and the beginning of baseline data collection
(30 min of lactated Ringer infusion at all sites + 60 min
drug perfusion), a period of time sufficient to ensure that
any tissue redness associated with fiber insertion had sub-
sided (Anderson et al. 1994). Since this drug infusion was
performed in the heat (35°C), the participants were pre-
exposed to a sufficiently prolonged ambient heat stress
prior to data collection. As such, we were also able to
assess the influence of a passive heat stress on heat loss
responses which has been shown to be attenuated in older
adults with (Kenny et al. 2016a) and without type 2 dia-
betes (Kenny et al. 2015) relative to young adults.
After the >60 min drug infusion period, 10-min of
baseline resting measurements were taken in the heat
(35°C). Thereafter, the participants completed two 30-
min bouts of cycling at a fixed rate of metabolic heat
production of ~500 W (Control: 480  32; T2D:
500  7 W; P = 0.12). A fixed heat load was employed
to ensure a similar thermal drive, and therefore stimulus
for sweating, between individuals (Gagnon et al. 2013).
This resulted in a similar exercise intensities as defined by
%peak oxygen uptake in the Control and T2D groups of
68  4 and 72  5%, respectively (P = 0.22). The first
and second bouts of exercise were followed by 20- and
40-min recovery periods. In this study we employed two
bouts of exercise in order to evaluate the mechanisms
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2017 | Vol. 5 | Iss. 7 | e13238
Page 3
N. Fujii et al. Ascorbate Infusion and Heat Loss
underpinning the regulation of heat loss responses during
and following successive exercise cycles. Studies show that
the heat loss responses are rapidly attenuated in the first
15-min following cessation of exercise despite progressive
increases in body core temperature with successive exer-
cise bouts. However, the heat loss responses are activated
more quickly in subsequent exercise bouts. These differ-
ences have been shown to have an important effect on
body core temperature regulation. We employed a longer
40-min recovery period following the second exercise
bout to ensure that stable values had been achieved. Fol-
lowing the second 40-min recovery period, 50 mmol/L
sodium nitroprusside (Sigma-Aldrich) was administered
at all four microdialysis sites at a rate of 6.0 lL/min for
20–30 min in order to achieve maximal cutaneous vasodi-
lation. Thereafter, all equipment were removed, and post-
experiment body mass was recorded.
Measurements
We employed the 1.1 cm2 ventilated sweat capsule which
was designed for the evaluation of local forearm sweat
rate when employing intradermal microdialysis (Meade
et al. 2016). Local sweat rate was estimated based on
sweat production evaluated under the sweat capsules,
which were positioned over the center of each microdialy-
sis membrane and affixed to the skin with adhesive rings
and topical skin glue (Collodion HV, Mavidon Medical
products, Lake Worth, FL). To evaporate all sweat pro-
duced under the capsule, dry compressed air from gas
tanks located in the thermal chamber was supplied to
each capsule at a constant rate. The water content of the
effluent air was measured with a capacitance hygrometer
(Model HMT333, Vaisala, Helsinki, Finland). Local fore-
arm sweat rate was calculated every 5 sec using the differ-
ence in humidity between influent and effluent air,
multiplied by the flow rate, and normalized to the skin
surface area under the capsule (mg/min/cm2).
Cutaneous red blood cell flux, expressed in perfusion
units (index of cutaneous blood flow), was locally mea-
sured at a sampling rate of 32 Hz with laser-Doppler
flowmetry (PeriFlux System 5000, Perimed, Stockholm,
Sweden). An integrated laser-Doppler flowmetry probe
with a 7-laser array (Model 413, Perimed) was placed in
the center of each sweat capsule directly over each micro-
dialysis fiber. Systolic and diastolic blood pressures were
measured by manual auscultation using a mercury column
sphygmomanometer (Baumanometer Standby Model, WA
Baum Co, Copiague, NY). Mean arterial pressure was cal-
culated as diastolic arterial pressure plus one-third the dif-
ference between systolic and diastolic pressures (pulse
pressure). Cutaneous vascular conductance (CVC) was cal-
culated as cutaneous red blood cell flux divided by mean
arterial pressure. CVC data were normalized at each site as
percentage of maximum (expressed as %CVCmax). Maxi-
mum CVC was obtained during the administration of
sodium nitroprusside at the end of the experiment. Heart
rate was recorded every 5 sec using a heart rate monitor
(RS400, Polar Electro, Kempele, Finland).
Body core temperature was measured using a thermo-
couple temperature probe (Mon-a-therm, Mallinckrodt
Medical, St Louis, MO) inserted in the esophagus or rec-
tum. For participants unable to tolerate the insertion of
these probes, a temperature sensor (Braun ThermoScan
PRO 6000, Welch Allyn, Skaneateles Falls, New York)
inserted in the aural canal was employed to estimate body
core temperature. Skin temperature was measured using
thermocouples (Concept Engineering, Old Saybrook, CT)
attached to the skin with adhesive rings and surgical tape.
Mean skin temperature was estimated as a weighted mean
value using local skin temperatures measured at four sites
(20% calf, 20% quadriceps, 30% biceps, and 30% chest)
according to the equation used by Hardy and Dubois
(1938). Esophageal, rectal, and skin temperature data
were sampled at 15 sec intervals using a data acquisition
module (Model 34970A; Agilent Technologies Canada
Inc., Mississauga, ON, Canada) and simultaneously dis-
played and recorded in spreadsheet format on a personal
computer with LabVIEW software (Version 7.0, National
Instruments, Austin, TX). Aural canal temperature was
recorded every 5 min.
Metabolic rate was determined using indirect calorime-
try (MOXUS system, Applied Electrochemistry, Pitts-
burgh, PA) where expired gases were analyzed for oxygen
and carbon dioxide concentrations. Approximately 20 min
before the start of baseline resting data collection, gas mix-
tures of known concentrations were used to calibrate gas
analyzers and a 3 L syringe was used to calibrate the tur-
bine ventilometer. The subjects wore full face masks
(Model 7600 V2, Hans-Rudolph, Kansas City, MO)
attached to a 2-way T-shape nonrebreathing valve (Model
2700, Hans-Rudolph). Oxygen uptake and respiratory
exchange ratio were obtained every 30 sec and were used
to calculate metabolic rate (Nishi 1981; Kenny and Jay
2013). Metabolic heat load was estimated as metabolic rate
minus the external work (i.e., work rate during cycling).
For the safety of participants with type 2 diabetes,
blood glucose concentration was monitored using a blood
glucose meter (Contour Next, Bayer AG, Leverkusen,
Germany).
Data analysis
All data used for data analysis were obtained by averaging
values over the last 5 min of each time period, with the
exception of absolute maximal CVC (perfusion
2017 | Vol. 5 | Iss. 7 | e13238
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units.mmHg1) obtained during sodium nitroprusside
administration (peak values averaged over 2 min). The
contribution of NOS to cutaneous vasodilation occurring
during the last 5 min of each exercise bout was evaluated
as the difference (Δ) in CVC between the vehicle control
and L-NAME sites. Similarly, the NOS contribution in the
presence of ascorbate was also evaluated by ΔCVC
between the vehicle control and ascorbate + L-NAME
sites. Due to technical difficulties, the measurement of
one CVC, heart rate, body core temperature, and percent
body fat as well as three skin temperatures from the T2D
group, and one body core temperature from the Control
group were not acquired.
Statistical analysis
Local forearm CVC and sweat rate were analyzed using a
three-way mixed-design analysis of variance with factors
of treatment site (four levels: vehicle control, ascorbate,
L-NAME, ascorbate + L-NAME), time (six levels: baseline,
exercise 1, recovery 1, exercise 2, recovery 2 at 20 and
40 min), and group (two levels: Control and T2D). Body
temperatures and cardiovascular variables were analyzed
using a two-way mixed-design analysis of variance with
factors of time (six levels) and group (two levels). Abso-
lute maximal CVC (expressed in perfusion units/mmHg)
attained during sodium nitroprusside infusion was ana-
lyzed using a two-way mixed-design analysis of variance
with factors of treatment site (four levels) and group
(two levels). When a significant interaction or main effect
was observed, post hoc multiple comparisons were con-
ducted using the modified Bonferroni procedures [i.e.,
Holm procedure (Gordon and Salzman 2008)]. Student’s
pairwise and nonpairwise t-tests were employed for
between-site and between-group comparisons, respec-
tively. The level of significance for all analyses was set at
P ≤ 0.05, and all values are reported as mean  95%
confidence interval, unless otherwise noted. All statistical
tests were performed using the software package SPSS 24
for Windows (IBM, Armonk, NY).
Results
Participant characteristics
Age, body mass, body surface area, body fat, and absolute
peak oxygen uptake were not different between groups,
whereas height and peak oxygen uptake relative to body
mass were lower in the T2D group (Table 1).
Cutaneous vascular conductance
Main effects of treatment site, time, and group, as well as
an interaction between time and group were detected for
CVC (Fig. 1, Table 2, all P ≤ 0.05). There was an interac-
tion between treatment site and group for ΔCVC (Fig. 2,
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Figure 1. Cutaneous vascular conductance evaluated at the last 5 min of the first (Ex 1) and second (Ex 2) 30-min exercise in older healthy
adults (Control, panel A) and those with type 2 diabetes (T2D, panel B). Cutaneous vascular conductance was evaluated at four skin sites treated
with either 1) lactated Ringer (vehicle control site), 2) ascorbate, an antioxidant, 3) L-NAME, a nitric oxide synthase inhibitor, or 4) ascorbate +
L-NAME. Data are expressed as mean  95% confidence interval. *, versus vehicle control site (P ≤ 0.05). †, versus Control group (P ≤ 0.05).
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P = 0.02). No main effects of treatment site and group
and their interaction were measured for absolute maximal
CVC (Table 2, all P > 0.05).
Control group
In the Control group, independent infusion of ascorbate
did not affect CVC relative to the vehicle control site at
any time point (all P > 0.05, Fig. 1A and Table 2). In
contrast, L-NAME reduced CVC in comparison to the
vehicle control site throughout the experiment (all
P ≤ 0.05) with the exception of at 40 min into second
recovery period, where CVC tended (P = 0.07) to be
lower at the L-NAME relative to vehicle control site
(Fig. 1A, Table 2). Combined infusion of ascorbate and
L-NAME also attenuated CVC relative to the vehicle
Table 2. Cutaneous vascular conductance measured during baseline rest (before exercise) and postexercise recovery periods as well as that
evaluated during sodium nitroprusside administration (absolute maximum).
%CVCmax
(Perfusion units/mmHg)
Baseline rest Rec 1 at 20 min Rec 2 at 20 min Rec 2 at 40 min
Sodium nitroprusside
administration
Control group
Vehicle control 36  11 44  9 45  10 39  9 1.73  0.40
Ascorbate 40  8 51  7 51  7 51  10 1.89  0.43
L-NAME 18  51 25  61 27  91 25  7 1.70  0.29
Ascorbate + L-NAME 21  7 28  61 25  61 27  7 1.82  0.43
T2D group
Vehicle control 42  6 57  82 59  92 53  72 2.02  0.48
Ascorbate 42  7 56  9 65  52 58  8 1.97  0.52
L-NAME 30  102 46  152 47  112 41  102 1.68  0.32
Ascorbate + L-NAME 25  51 37  111 37  81,2 34  91 1.66  0.40
All values are expressed as mean  95% confidence interval. Data were obtained by averaging values over the last 5 min at each time period.
Ascorbate, an antioxidant; L-NAME, a nitric oxide synthase inhibitor; Rec, recovery; T2D, type 2 diabetes; CVC, Cutaneous vascular conduc-
tance.
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2versus Control group (P ≤ 0.05).
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Figure 2. Pharmacological treatment-induced change (Δ) in cutaneous vascular conductance from lactated Ringer site (vehicle control site) in
older healthy adults (Control, panel A) and those with type 2 diabetes (T2D, panel B). Cutaneous vascular conductance measured at the last
5 min of the first (Ex 1) and second (Ex 2) 30-min exercise was used for data analysis. Pharmacological treatments employed were 1) L-NAME,
a nitric oxide synthase inhibitor, or 2) ascorbate (an antioxidant) + L-NAME. Data are expressed as mean  95% confidence interval. †, versus
Control group (P ≤ 0.05).
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control site during the second exercise and first recovery
as well as the first 20-min of the second recovery period
(all P ≤ 0.05, Fig. 1A, Table 2). The magnitude of reduc-
tion in CVC (ΔCVC) induced by L-NAME during exer-
cise was similar with and without co-administration of
ascorbate (Fig. 2A).
T2D group
In the T2D group, administration of ascorbate did not
affect CVC in comparison to the vehicle control site at
any time point (all P ≤ 0.05, Fig. 1B, Table 2). L-NAME
attenuated CVC in relation to the vehicle control site
during each exercise bout (all P ≤ 0.05, Fig. 1B) but
not during baseline resting and each recovery periods
(all P > 0.05, Table 2). On the other hand, L-NAME in
combination with ascorbate reduced CVC throughout
the experiment (all P ≤ 0.05, Fig. 1B, Table 2). Further,
when compared to the vehicle control site, the
difference in CVC with L-NAME administration was
greater in the presence versus absence of co-administra-
tion of ascorbate during exercise (both P = 0.01,
Fig. 2B).
Between-group comparison
During both exercise bouts, the magnitude of the reduc-
tion in CVC induced by L-NAME administration alone
was similar between groups (both P > 0.05, Fig. 2). In
contrast, the reduction in CVC elicited by L-NAME
combined with ascorbate was greater in the T2D com-
pared with Control group during the second exercise
(P ≤ 0.05, Fig. 2). CVC measured at the vehicle control
site did not differ between groups during baseline or
each exercise, but was higher during each of the two
recovery periods in the T2D relative to the Control
groups (Table 2).
Sweat rate
A main effect of time and an interaction between time
and group were detected for sweat rate (Fig. 3, Table 3,
all P ≤ 0.05). However, there were no between-site or
between-group differences in sweat rate throughout the
experiment (all P > 0.05, Fig. 3 and Table 3).
Cardiovascular and thermal responses
A main effect of time was found for heart rate, whereas a
main effect of time and an interaction between time and
group were measured on mean skin temperature and
mean arterial pressure (Table 4, all P ≤ 0.05). Main
effects of time and group and an interaction between time
and group were detected for body core temperature
(Table 4, all P ≤ 0.05). Heart rate, mean arterial pressure,
and mean skin temperature did not differ between groups
throughout the protocol (all P > 0.05) with the exception
of lower mean skin temperature during baseline rest in
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Figure 3. Sweat rate evaluated at the last 5 min of the first (Ex 1) and second (Ex 2) 30-min exercise in older healthy adults (Control, panel A)
and those with type 2 diabetes (T2D, panel B). Sweat rate was evaluated at four skin sites treated with either 1) lactated Ringer (vehicle control
site), 2) ascorbate, an antioxidant, 3) L-NAME, a nitric oxide synthase inhibitor, or 4) ascorbate + L-NAME. Data are expressed as mean  95%
confidence interval. Values did not differ between sites and groups (all P > 0.07).
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the T2D group (P ≤ 0.05, Table 4). Body core tempera-
ture was higher in the T2D group as compared to the
Control group during the second exercise and both recov-
ery periods (all P ≤ 0.05, Table 4).
Blood glucose
Blood glucose in the T2D group at baseline rest was
8.8  1.2 mmol/L, which decreased to 7.3  0.7 mmol/L
at the end of second recovery (P = 0.05).
Body weight loss
A similar reduction in body weight following exercise in
the heat was measured in the Control and T2D groups
(1.4  0.1 vs. 1.6  0.3 kg, P = 0.27).
Discussion
We are the first to examine the effect of intradermal
ascorbate administration on the regulation of cutaneous
Table 3. Sweat rate measured during baseline rest (before exercise) and postexercise recovery periods.
(mg/min/cm2)
Baseline rest Rec 1 at 20 min Rec 2 at 20 min Rec 2 at 40 min
Control group
Vehicle control 0.25  0.05 0.62  0.08 0.70  0.10 0.49  0.07
Ascorbate 0.26  0.06 0.72  0.08 0.79  0.10 0.60  0.07
L-NAME 0.24  0.05 0.69  0.08 0.72  0.10 0.53  0.07
Ascorbate + L-NAME 0.26  0.05 0.65  0.11 0.72  0.13 0.52  0.09
T2D group
Vehicle control 0.35  0.07 0.81  0.23 0.94  0.27 0.71  0.18
Ascorbate 0.34  0.06 0.71  0.16 0.81  0.17 0.64  0.13
L-NAME 0.35  0.07 0.77  0.16 0.81  0.15 0.67  0.13
Ascorbate + L-NAME 0.34  0.07 0.68  0.20 0.77  0.21 0.63  0.19
All values are expressed as mean  95% confidence interval. Data were obtained by averaging values over the last 5 min at each time period.
Ascorbate, an antioxidant; L-NAME, a nitric oxide synthase inhibitor; Rec, recovery; T2D, type 2 diabetes. There were no between-site and
between-group differences (all P > 0.07).
Table 4. Cardiovascular and body temperature responses measured during baseline rest (before exercise) and the two exercise and recovery
periods.
Baseline rest Ex 1 at 30 min Rec 1 at 20 min Ex 2 at 30 min
Rec 2
at 20 min at 40 min
Heart rate (bpm)
Control group 71  5 121  101 85  91 128  121,2 90  111,2 86  91
T2D group 77  8 128  111 100  131 136  111,2 106  131,2 98  111
Mean arterial pressure (mmHg)
Control group 99  4 107  51 95  5 105  6 93  41 91  41,2
T2D group 97  5 112  31 96  4 109  51 92  5 89  51,2
Mean skin temperature (°C)
Control group 34.94  0.30 35.37  0.311 34.86  0.33 35.35  0.49 34.96  0.35 34.43  0.351,2
T2D group 34.38  0.243 35.50  0.371 35.30  0.271 35.65  0.431 35.42  0.391 34.92  0.421,2
Body core temperature (°C)
Control group 37.01  0.16 37.81  0.181 37.37  0.101 37.99  0.241 37.45  0.141 37.35  0.131
T2D group 37.07  0.20 37.98  0.191 37.81  0.211,3 38.34  0.231,2,3 38.18  0.311,2,3 37.87  0.231,3
Values are mean  95% confidence interval. Data were obtained by averaging values over the last 5 min at each time period.
Ex, exercise; Rec, recovery; T2D, type 2 diabetes. bpm, beats per minute.
1versus baseline rest (P ≤ 0.05).
2Ex 1 versus 2 or Rec 1 versus 2 (P ≤ 0.05).
3versus Control group (P ≤ 0.05).
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vasodilation and sweating in healthy older adults and
those with type 2 diabetes exercising in the heat. Our
results suggest that during exercise in the heat, ascorbate
does not modulate the heat loss responses of cutaneous
vasodilation and sweating in both healthy older adults
and those with type 2 diabetes. However, we show that
NOS is an important contributor to the regulation of
cutaneous vasodilation in both groups.
Cutaneous vascular response
Our results demonstrated no effect of ascorbate on CVC
during exercise in the heat in healthy older adults
(Fig. 1A) and this response remained intact during base-
line rest as well as post-exercise recovery (Table 2). This
is in contrast to a previous report by Holowatz et al.
(2006) in which ascorbate augmented cutaneous vasodila-
tion during passive heating at rest using a water-perfu-
sion suit. The reason underlying this discrepancy is
unknown, but the influence of ascorbate on cutaneous
vasodilation during heat stress may differ depending on
the level of mean skin temperature. Mean skin tempera-
ture in the present study was ~35°C (Table 4). In con-
trast, while mean skin temperature was not reported by
Holowatz et al. (2006), the temperature measured in
their study would likely have been higher (e.g., ~39°C).
This is supported by the observations by Brunt et al.
(2013) using a similar heating procedure with a water-
perfusion suit. Higher skin temperature may induce
greater increase in oxidative stress, as a previous report
demonstrated that oxidative marker (malondialdehyde)
was greater during exercise performed in moderate
(32°C) versus cool (12°C) ambient temperature condi-
tions (Sureda et al. 2015). Hence, the level of oxidative
stress in the present study might not have been high
enough to affect cutaneous vascular response.
We show for the first time that ascorbate had no
effect on cutaneous vasodilation during a passive or
exercise-induced heat stress in older adults with well
controlled type 2 diabetes (Fig. 1B, Table 2). Although
ascorbate may be effective in improving vasodilation
response in forearm conduit artery in individuals with
type 2 diabetes (Montero et al. 2014), its influence on
markers of oxidative stress (Rytter et al. 2010) and dia-
betic complications (Rahimi-Madiseh et al. 2016) are rel-
atively minor; a response comparable to that observed
on skin vessels in the present study. It should be noted
that we employed individuals with well-controlled type 2
diabetes without the presence of peripheral neuropathy
or other diabetic complications. Sweating function may
be further impaired in individuals with poor glycemic
control and/or the presence of peripheral neuropathy
(Luo et al. 2012; Kenny et al. 2016b). Thus, the potential
exists that the therapeutic benefits of ascorbate in
enhancing heat dissipation may be most evident in heat-
vulnerable individuals. However, this possibility requires
future scrutiny.
The present study demonstrated that NOS contributes
to the regulation of cutaneous vasodilation during exer-
cise in the heat in relatively healthy older adults (Fig. 1A),
which is in accordance with previous reports using pas-
sive heating at rest (Holowatz et al. 2003; Stanhewicz
et al. 2012) and exercise in the heat (Fujii et al. 2015b,
2016b). Our results also demonstrate that NOS con-
tributes to cutaneous vasodilation in individuals with
T2D during exercise in the heat (Fig. 1B). Furthermore,
the magnitude of the contribution of NOS as evaluated
by the L-NAME-induced reduction in CVC from the
vehicle control site did not differ between groups during
exercise in the heat (Fig. 2). This is consistent with a pre-
vious report assessing the response during passive heating
at rest (Sokolnicki et al. 2009). Therefore, our results in
combinations with the findings of others (Sokolnicki
et al. 2009) suggest that type 2 diabetes does not blunt
NOS-dependent cutaneous vasodilation irrespective of the
nature of the heat stress (i.e., a passive or exercise-
induced heat stress).
Interestingly, we observed that the influence of the
combined administration of ascorbate and L-NAME on
cutaneous vasodilation during exercise differed between
the Control and T2D groups (Fig. 2). Specifically, in the
Control group, the reduction in CVC induced by the
combined administration of ascorbate and L-NAME was
similar to the response measured with the administration
of L-NAME only (Fig. 2A). In contrast, we showed that
the reduction in CVC was greater than that achieved with
L-NAME alone in the T2D group (Fig. 2B). Based on
these results, it appears that in the absence of NO pro-
duction, ascorbate seems to further attenuate cutaneous
vasodilation in individuals with type 2 diabetes. More
work is required to assess the mechanisms underpinning
this response.
We found that CVC measured at the vehicle control
site was higher during the recovery periods in the T2D as
compared with the Control group (Table 2). It is unclear
why the T2D group exhibited a higher CVC response
during the postexercise recovery period only, but a higher
body core temperature and therefore greater thermal
drive may be involved (Table 4). In contrast to our find-
ings, previous studies have shown that type 2 diabetes
attenuates cutaneous vasodilation during passive heating
at rest (Wick et al. 2006; Sokolnicki et al. 2009). How-
ever, these previous studies employed a different heat
stress protocol (whole-body heating with a water-perfused
suit) that makes a direct comparison of responses
difficult.
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Sweating response
We found that ascorbate did not influence sweat rate rel-
ative to the vehicle control site during exercise (Fig. 3) as
well as during resting and postexercise recovery (Table 3)
in the heat in either group. Hence, ascorbate does not
appear to enhance sweating in healthy older adults and
those with type 2 diabetes under the conditions exam-
ined. On the other hand, in keeping with our previous
studies (Stapleton et al. 2014; Fujii et al. 2015b, 2016b),
we confirmed no role for NOS in the regulation of
sweating during exercise in the heat in healthy older
adults (Fig. 3), which is in contrast to findings in
younger adults (Welch et al. 2009; Stapleton et al. 2014;
Fujii et al. 2016b). Since no contribution of NOS to
sweating during exercise in the heat was also observed in
the T2D group (Fig. 3), the age-related reduction in
NOS-dependent sweating is present irrespective of the
presence of type 2 diabetes. While the mechanisms
underpinning these findings are currently unclear,
increased oxidative stress associated with aging might not
be involved given that ascorbate perfusion did not influ-
ence the sweating response when administered alone or
in combination with L-NAME. Further research is war-
ranted to delineate the mechanisms mediating the age-
related attenuation in NOS-dependent sweating during
exercise in the heat.
As with cutaneous vasodilation, our results demonstrate
that type 2 diabetes does not modulate local forearm
sweat rate during exercise in the heat (Fig. 3), which is
consistent with our previous work (Kenny et al. 2013).
Noteworthy, the same study showed that whole-body
sweating during exercise is indeed attenuated in individu-
als with T2D (Kenny et al. 2013). Therefore, it is likely
that the influence of type 2 diabetes on sweating during
exercise in the heat is site-specific. Attenuations in whole-
body sweating and thus heat loss is indirectly supported
by the fact that we observed a greater increase in body
core temperature in the T2D versus Control group after
the first exercise (Table 4). Further studies are required to
evaluate regional responses associated with diabetes-
related modulation of the sweating response.
Considerations
We did not directly assess levels of ascorbate/vitamin C
and oxidative stress in the Control and T2D groups. It is
therefore possible that our findings are simply a product
of including participants in both groups with relatively
similar levels of systemic inflammation/oxidative stress.
By design, we examined the influence of local ascorbate
infusion in individuals with well-controlled type 2 dia-
betes. It is possible however, that relative to their healthy
counterparts, differences in levels of systemic inflamma-
tion/oxidative stress may be more pronounced in individ-
uals with type 2 diabetes who have poor glycemic control
and or who are affected by diabetes-related complica-
tions. Factors such as medication use may also play an
important role in modulating this response. However,
given our T2D participants were on several different
medications, our results do not provide information per-
taining to which medication may have influenced the
observed findings.
Perspectives and significance
Older individuals are at greater risk of heat-related inju-
ries (Worfolk 2000; Kenney et al. 2014; Kenny et al.
2016b), and type 2 diabetes can exacerbate this risk
(Semenza et al. 1999; Kenny et al. 2016b). Hence the
development of interventions to augment heat dissipa-
tion and circumvent potentially dangerous increases in
body core temperature is of the utmost importance.
Based on the results obtained in this study, we show that
ascorbate does not improve the heat loss responses
through cutaneous vasodilation and sweating in healthy
older adults and those with type 2 diabetes during exer-
cise as well as resting before and after exercise in the
heat. Therefore, oral supplementation of ascorbate may
not be an effective therapeutic strategy to reverse age-
and diabetes-related impairments in heat loss in these at-
risk populations.
Conclusion
We show that intradermal administration of ascorbate
does not affect cutaneous vasodilation and sweating dur-
ing exercise in the heat in both healthy older adults and
those with type 2 diabetes. We also show that in both
groups, NOS contributes to the regulation of cutaneous
perfusion during exercise in the heat.
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